Parameter
| Biomarker | HER2 | Full name | Human epidermal growth factor receptor 2 | Molecular Type | Protein / Nucleic acid |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, prognosis |
| Disease | Breast Cancer | Disease Subtypes | / | ||
| Organ | Breast | Test Sample / Technology Platform | Tumor tissues (IHC, fluorescence in situ hybridization FISH, chromogenic in situ hybridization CISH); ctDNA (NGS) | ||
| Pathobiological Mechanisms | HER2 gene amplification or protein overexpression leads to continuous activation of the receptor, activating downstream RAS-MAPK and PI3K-AKT pathways, which drives rapid tumor proliferation. | ||||
| Clinical Availability Status | Clinical routine (recommended by guidelines): IHC + FISH/CISH is the gold standard for HER2 testing, guiding anti-HER2 treatment (trastuzumab, pertuzumab, ADC drugs) | ||||
| Notes and Dynamics | The new HER2 ADC drugs (such as DS-8201, T-DM1) are effective for patients with low HER2 expression or resistance; HER2 mutation testing (such as S310F) expands the treatment population. | ||||